ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 155 filers reported holding ASCENDIS PHARMA A/S in Q3 2020. The put-call ratio across all filers is 0.38 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,781 | -5.0% | 1,162 | -9.5% | 0.00% | – |
| Q2 2023 | $114,554 | +5.1% | 1,284 | +26.3% | 0.00% | – |
| Q1 2023 | $108,993 | +3.8% | 1,017 | +18.0% | 0.00% | – |
| Q4 2022 | $105,000 | +6.1% | 862 | -9.2% | 0.00% | – |
| Q3 2022 | $99,000 | +22.2% | 949 | +9.0% | 0.00% | – |
| Q2 2022 | $81,000 | +6.6% | 871 | +33.8% | 0.00% | – |
| Q1 2022 | $76,000 | -16.5% | 651 | -3.7% | 0.00% | – |
| Q4 2021 | $91,000 | -71.1% | 676 | -65.9% | 0.00% | -100.0% |
| Q3 2021 | $315,000 | +14.5% | 1,980 | -5.5% | 0.00% | 0.0% |
| Q2 2021 | $275,000 | +1.1% | 2,095 | -0.8% | 0.00% | 0.0% |
| Q1 2021 | $272,000 | -11.7% | 2,112 | +14.7% | 0.00% | 0.0% |
| Q4 2020 | $308,000 | +15.8% | 1,841 | +6.5% | 0.00% | 0.0% |
| Q3 2020 | $266,000 | +28.5% | 1,729 | +23.1% | 0.00% | 0.0% |
| Q2 2020 | $207,000 | +1781.8% | 1,405 | +1264.1% | 0.00% | – |
| Q1 2020 | $11,000 | – | 103 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |